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Abstract
Background: I'm-Yunity™ (PSP) is a mushroom extract derived from deep-layer cultivated mycelia of
the patented Cov-1 strain of Coriolus versicolor (CV), which contains as its main bioactive ingredient a family
of polysaccharo-peptide with heterogeneous charge properties and molecular sizes. I'm-Yunity™ (PSP) is
used as a dietary supplement by cancer patients and by individuals diagnosed with various chronic diseases.
Laboratory studies have shown that I'm-Yunity™ (PSP) enhances immune functions and also modulates
cellular responses to external challenges. Recently, I'm-Yunity™ (PSP) was also reported to exert potent
anti-tumorigenic effects, evident by suppression of cell proliferation and induction of apoptosis in malignant
cells. We investigate the mechanisms by which I'm-Yunity™ (PSP) elicits these effects.
Methods: Human leukemia HL-60 and U-937 cells were incubated with increasing doses of aqueous
extracts of I'm-Yunity™ (PSP). Control and treated cells were harvested at various times and analyzed for
changes in: (1) cell proliferation and viability, (2) cell cycle phase transition, (3) induction of apoptosis, (4)
expression of cell cycle, apoptogenic/anti-apoptotic, and extracellular regulatory proteins.
Results: Aqueous extracts of I'm-Yunity™ (PSP) inhibited cell proliferation and induced apoptosis in HL-
60 and U-937 cells, accompanied by a cell type-dependent disruption of the G1/S and G2/M phases of cell
cycle progression. A more pronounced growth suppression was observed in treated HL-60 cells, which
was correlated with time- and dose-dependent down regulation of the retinoblastoma protein Rb,
diminution in the expression of anti-apoptotic proteins bcl-2 and survivin, increase in apoptogenic proteins
bax and cytochrome c, and cleavage of poly(ADP-ribose) polymerase (PARP) from its native 112-kDa form
to the 89-kDa truncated product. Moreover, I'm-Yunity™ (PSP)-treated HL-60 cells also showed a
substantial decrease in p65 and to a lesser degree p50 forms of transcription factor NF-κB, which was
accompanied by a reduction in the expression of cyclooxygenase 2 (COX2). I'm-Yunity™ (PSP) also
elicited an increase in STAT1 (signal transducer and activator of transcription) and correspondingly,
decrease in the expression of activated form of ERK (extracellular signal-regulated kinase).
Conclusion: Aqueous extracts of I'm-Yunity™ (PSP) induces cell cycle arrest and alterations in the
expression of apoptogenic/anti-apoptotic and extracellular signaling regulatory proteins in human leukemia
cells, the net result being suppression of proliferation and increase in apoptosis. These findings may
contribute to the reported clinical and overall health effects of I'm-Yunity™ (PSP).
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Background
Throughout history, mushroom and mushroom products
have always been revered as food delicacies and are also
held in high esteem for their overall health benefits in
many cultures, particularly the Orient [1-4]. In East Asian
societies, a variety of mushrooms are sold either fresh or
as dietary supplements. These products are frequently
consumed depending on season of the year as prophylac-
tic measures for common ills and to improve the general
well-being of individuals [5]. The notable regard mush-
rooms are given for promoting wellness of the public at
large is perhaps in part attributed to the rather extensive
anecdotal and scientific evidence reporting their disease
preventive properties, focusing mostly on the potentia-
tion of immune functions and regulation of biological
responses [3,4,6]. Beginning in the 1990s, however, it has
become increasingly clear that mushrooms, mushroom
extracts, and indeed plant/botanical polysaccharides in
general, have activities beyond that of the immune sys-
tem, with suppression of tumorigenesis having the most
medical relevance and significance [7-10]. Thus, for
instance, polysaccharides with 6-branched 1,3-β glucan
structures isolated from the cultured fruit body of edible
mushroom  Sparassis crispa reportedly show antitumor
activity when tested against Sarcoma 180 in the ICR strain
mice [11,12]. Antineoplastic activity has been demon-
strated in polysaccharides isolated from Pleurotus tuber-
regium  [13], and from fruit body of cultivated Agricus
blazei  [14,15]. Several polysaccharide-peptide, and
polysaccharide-protein complexes with immunomodula-
tory and antitumor activities have been isolated and puri-
fied from mycelia cultures of Tricholoma Sp., an edible
mushroom native to Hong Kong [16-18]. Maitake, a
mushroom indigenous to northeastern Japan, is recog-
nized as a rich source of polysaccharides with a wide-
range of biological and medicinal properties [19,20].
Most notably, gel-purified D-fraction from Maitake char-
acterized as heterogeneous β-(1→6)-branched β-(1→3)-
linked alkali-soluble and acid-insoluble polysaccharides
[21], show bioactivities spanning the control of immune
response, suppression of tumor proliferation, induction
of apoptosis, inhibition of metastasis, and regulation of
angiogenesis [10,21,22]. Additionally, mushrooms
reportedly also contain antitumor proteins capable of
inducing apoptosis as well as cell cycle checkpoint arrest
in cultured malignant cells [23].
Dietary supplements derived from edible mushroom
known as Yunzhi, or Coriolus versicolor (Trametes versicolor,
Fr.) – known as one of six Zhi's recorded in the "Shen Non
Compendium Medica" some 2000 years ago – reportedly
also show a number of medicinal properties [2,24,25].
Structural and functional analyses of Yunzhi have bene-
fited from the discovery of the patented Cov-1 strain of
Coriolus versicolor in 1984–1987 by Yang and coworkers,
through an exhaustive screen of a large number of strains
of Yunzhi [1,4,26]. Subsequently, an innovative industrial
scale cultivation method using the mycelia of Cov-1 was
developed, which led to the serendipitous discovery, iso-
lation and purification of a family of polysaccharo-pep-
tide, denoted I'm-Yunity™ (PSP) [4,25,27].
I'm-Yunity™ (PSP) has demonstrated potent immu-
nomodulatory and antitumor activities in tissue culture
studies, based principally on data using flow cytometry
[27-31]. In previous studies, we have observed that etha-
nol and water extracts of I'm-Yunity™ (PSP) exerted dose-
and time-dependent anti-proliferative effects in human
promyelocytic HL-60 leukemic cells. Flow cytometric
analyses showed that low doses of ethanol and water
extracts of I'm-Yunity™ (PSP) induced partial cell arrest in
the G1 phase, whereas high doses resulted in apoptotic cell
death. Moreover, water extracts were found to have signif-
icantly more pronounced anti-cellular effects than etha-
nol extracts [28]. In addition, water and ethanol extracts
of I'm-Yunity™ (PSP) markedly increased the secretion of
IL-1β and IL-6 with concomitant reduction of IL-8 in HL-
60 cells, while having no affect on growth and lym-
phokine expression in normal human lymphocytes [28].
The molecular details by which I'm-Yunity™ (PSP) exerts
its biological effects remain incompletely understood.
To further investigate the mechanism of action of I'm-
Yunity™ (PSP), we studied the effects of water extracts of
I'm-Yunity™ (PSP) on growth, viability and cell cycle
traverse using human HL-60 and U-937 leukemia cells.
We found a similar degree of inhibition of cell growth and
induction of apoptosis, accompanied by differential tar-
geting of G1/S and G2/M cell cycle phase transition,
respectively, in the HL-60 and U-937 cells. Furthermore,
in HL-60 cells, we showed that growth suppression by
water extracts of I'm-Yunity™ (PSP) was correlated with
time- and dose-dependent inhibition of retinoblastoma
protein Rb expression. Correspondingly, induction of
apoptosis in I'm-Yunity™ (PSP)-treated cells – evident by
cleavage of poly(ADP-ribose) polymerase (PARP) from its
native 112-kDa form to the 89-kDa truncated product –
was matched by a significant decrease in the expression of
anti-apoptotic proteins bcl-2 and survivin, and an
increase in apoptogenic proteins bax and cytochrome c.
Moreover, HL-60 cells treated with I'm-Yunity™ (PSP) also
showed a diminished p65 and p50 forms of transcription
factor NF-κB, which paralleled the reduced expression of
COX2. We further observed that suppression of HL-60 cell
growth was positively correlated with an increase in signal
transducer and activator family of transcription factors
STAT1, and conversely, with reduction in the expression
of activated form of ERK. We postulate that the observed
cell cycle and apoptogenic/anti-apoptotic and extracellu-
lar signaling regulatory protein expression changes result-BMC Complementary and Alternative Medicine 2006, 6:30 http://www.biomedcentral.com/1472-6882/6/30
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ing from treatment by water extracts of I'm-Yunity™ (PSP)
are mechanistically linked to its reported clinical
attributes and general health beneficial effects.
Methods
Source of I'm-Yunity™ (PSP)
I'm-Yunity™ (PSP) was supplied by ICM Holdings Ltd.
(Hong Kong, China), as a mushroom product produced
from deep-layer cultivated mycelia of Cov-1 according to
Good Manufacturing Practice (GMP) standards. Briefly,
following a 2.5–3 day batch fermentation culture [27], the
biomass containing mycelia was extracted with hot water
at 95°C for 4–5 h. The aqueous extract was differentially
precipitated with ethanol, and fractionated using a propri-
etary scheme for enriching and retaining bioactive
polysaccharo-peptides with molecular weights >40-kDa
and an average polysaccharide:peptide ratio of 2:1 [28].
Additional quality control of I'm-Yunity™ (PSP) involved
determination of heavy metal contents, microorganism
contamination, authentication of elution profiles on high
pressure liquid chromatograph, and supplementary bio-
activity-guided assays, performed by laboratories at the
manufacturing facilities and also independently as coded
samples by commercial testing centers.
Preparation of water extracts of I'm-Yunity™ (PSP)
To prepare water extracts of I'm-Yunity™ (PSP), contents
of each capsule (containing 340 mg powder) were sus-
pended in 3.3 ml of water. The suspension was stirred
with intermittent mixing at 150 rpm for 60 minutes at
room temperature. The insoluble material was removed
by centrifugation in a micro-centrifuge. The soluble super-
natant was sterilized by passing through a 0.22 µm filter
and kept in aliquots at 4°C. Water extracts of I'm-Yunity™
were analyzed by SDS-PAGE followed by staining with
Coomassie blue, also using the Schiff's reagent from
Sigma (this reagent is modified from the Periodic acid-
Schiff (PAS) method and is designed to identify glycopro-
teins), and with Rapid-Ag-Stain from MP Biomedicals
(Figure 1A–C). Staining with Coomassie blue revealed a
major and minor band migrating with average molecular
weights of 45-kDa and 35-kDa, respectively (Figure 1A).
Gels stained with the Schiff's reagent showed a magenta
pattern with a very light pink background; the most
intensely stain corresponded to a very broad protein band
migrating in the vicinity of >45-kDa (Figure 1B). Silver
staining did not produce a distinct pattern (Figure 1C). As
a whole, these results supported the interpretation that
water extracts of I'm-Yunity™ (PSP) contain highly hetero-
geneous polysaccharo-peptides, with variable carbohy-
drate moieties linked to different side chain
monosaccharides.
Cell culture and growth inhibition assay
Human HL-60 and U-937 leukemia cells were obtained
from the American Type Culture Collection (ATCC, Rock-
ville, MD), and cultured as described [5,28,32-35]. For
treatment of either cell type, the stock aqueous extract of
I'm-Yunity™ (PSP) was first diluted in tissue culture media
and then added to cultured cells to give the final indicated
doses. In a typical experiment, 5 ml of cells at a density of
1 × 105 cells/ml were seeded in T25 flasks. Next, different
amounts of aqueous extracts of I'm-Yunity™ (PSP) were
added into the culture media. At the specified times, con-
trol and treated cells were harvested. Cell count was per-
formed using a hemocytometer and cell viability was
determined by trypan blue exclusion [5,28,34,35]. In
addition, cell viability of control and treated cells was also
measured using the MTT assay [35]. Harvested cells were
washed twice with PBS, and pellets were stored at -80°C
for additional biochemical and molecular analyses.
Analysis of constituents of water extracts of I'm-Yunity™  (PSP) by SDS-PAGE and staining with Coomassie blue (panel  A), Schiff's reagent from Sigma (panel B), and silver staining  reagent from MP Biomedicals (panel C) Figure 1
Analysis of constituents of water extracts of I'm-Yunity™ 
(PSP) by SDS-PAGE and staining with Coomassie blue (panel 
A), Schiff's reagent from Sigma (panel B), and silver staining 
reagent from MP Biomedicals (panel C). In each panel, lane 
M corresponds to the staining pattern of protein markers, 
with arrows pointing to the position of migration of different 
molecular weight proteins. Correspondingly, lane I shows the 
migration of samples of water extracts of I'm-Yunity™ (PSP) 
after they were separated on 10% SDS-PAGE. The patterns 
revealed by different stains support the interpretation that 
I'm-Yunity™ (PSP) is a family of heterogeneous carbohy-
drate-containing polypeptides.
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Effects of I'm-Yunity™ (PSP) on cell cycle progression
Cell cycle phase distribution was assayed by flow cytome-
try. Following a 3-day treatment of HL-60 or U-937 cells
with different amounts of water extract of I'm-Yunity™
(PSP) (0.1, 0.5, and 1.0 mg/ml), cells were washed with
PBS and stained with 1.0 µg/ml DAPI containing 100 mM
NaCl, 2 mM MgCl2 and 0.1% Triton X-100 (Sigma) at pH
6.8, as described [28,32,36-38]. The DNA-specific DAPI
fluorescence was excited with UV light emitting laser (Ni-
Cad), and collected with appropriate filters in an ICP-22
(Ortho Diagnostic, Westwood, MA) flow cytometer. Mul-
tiCycle software from Phoenix Flow Systems (San Diego,
CA) was used to deconvolute the cellular DNA content
histograms to obtain quantitation of the percentage of
cells in the respective phases (G1, S and G2/M) of the cell
cycle. Flow cytometry was also used to show cells under-
going apoptosis, evident by the appearance of the sub-G1
peak [32,39].
RNA isolation and quantitative real-time PCR of 
cyclooxygenase 2 (COX2)
COX2 mRNA expression was assayed using semi-quanti-
tative RT-PCR or quantitative real-time PCR [34,40-42].
Total cellular RNA was isolated from day 3 control and
I'm-Yunity™ (PSP) treated HL-60 cells using TRIzol rea-
gent (InVitrogen) according to protocols provided by the
manufacturer. RNA purity and quantitation was deter-
mined by agarose gel electrophoresis and A260/280 absorb-
ance ratio. First strand cDNA synthesis used 2 µl total RNA
incubated at 42°C for 50 min with Superscript RNase H-
reverse transcriptase (InVitrogen). A 10-fold diluted
cDNA served as the template for PCR. To amply and quan-
titate the human COX2 gene, PCR was performed using
the Lightcycler PCR system (Roche Diagnostics, Man-
nheim, Germany) in glass capillaries in a final volume of
20 µl with addition of 1× Lightcycler master mix, 3 mM
MgCl2, 1 µM of COX2 primer sets (sense 5'-ATG GGG
TGA TGA GCA GTT GT-3' and antisense 5'-TGA GGC AGT
GTT GAT GAT TTG-3'), and 2 µl of cDNA template or
external standard template. The amplification reaction
consisted of heating samples at 95°C for 30 s followed by
40 cycles of heating at 20°C/s to 95°C with a 1-s hold,
cooling at 20°C/s to 55°C with a 1-s hold, and heating at
20°C/s to 72°C with a 10-s hold. A melting curve was
generated by heating the product at 20°C/s to 95°C, cool-
ing it at 20°C/s to 60°C, and slowly heating at 0.2°C/s to
95°C, with fluorescence collection at 0.2°C intervals.
Human COX2 was amplified by conventional PCR and
cloned into PCR 2.1-TOPO vector (InVitrogen) for trans-
formation in TOP10 competent cells. Plasmid DNA con-
taining human COX2 was purified using the Mini Plasmid
Extraction Kit (Qiagen, Valencia, CA). Real-time PCR was
performed using the Light Cycler DNA Master SYBR Green
1 kit according to manufacturer's instructions. Ten fold
serial dilutions of the purified plasmid DNA containing
100 to 107 copies of COX2 in 2 µl were used as standards
to calculate COX2 mRNA copy number, which is
expressed as % of control. The data obtained were ana-
lyzed using the Lightcycler software provided by the man-
ufacturer. Only log-linear portion of amplification was
chosen for analysis. Experiments were performed in dupli-
cate.
Preparation of whole cell extracts and western blot 
analysis
Cells were suspended in buffer (50 µl/106 cells) contain-
ing 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% Triton X-
100, 1% sodium deoxycholate, 0.1% SDS, 1 mM EDTA, 1
mM PMSF, 5 µg/ml each of aprotinin, pepstatin, leupep-
tin, and lysed by 3 freeze/thaw cycles [33,42,43]. The
extracts were centrifuged and the clear supernatants were
stored in aliquots at -70°C. Ten to 20 µg of proteins were
separated on 10% SDS-PAGE. Membranes were probed
for expression of Rb, poly(ADP-ribose) polymerase
(PARP), bcl-2, survivin, bax, cytochrome c, p50 and p65
forms of NF-κB, STAT1, ERK, and β-actin. Commercial
antibodies (from Santa Cruz Biotechnology, Inc.) were
used at a dilution of 1:1000. Immunoreactivity was dem-
onstrated by enhanced chemiluminescence (ECL) or color
reaction, using the manufacturer's protocol (Kirkegared &
Perry Laboratories).
Preparation of subcellular fractions from control and 
treated HL-60 cells
Cytosolic and mitochondria fractions were obtained
using the Mitochondria isolation kit from Sigma. Har-
vested control and treated cells washed with ice-cold PBS
were suspended in extraction buffer containing 10 mM
Hepes, pH 7.5 supplemented with 200 mM mannitol, 70
mM sucrose, 1 mM EGTA, and 0.5 mg/ml BSA. The cell
suspension was homogenized by 30 passages through a
25-gauge needle. The homogenate was centrifuged at 600
× g, 5 min and the supernatant transferred to a fresh tube.
Further centrifugation of the supernatant at 11,000 × g, 10
min yielded a cytosolic supernatant and a mitochondria
pellet. The pellet was resuspended in extraction buffer and
centrifuged at 11,000 × g, 10 min. The mitochondria pel-
let was resuspended in 10 mM Hepes, pH 7.4 containing
250 mM sucrose, 1 mM ATP, 0.08 mM ADP, 5 mM
sodium succinate, 2 mM K2HPO4, and 1 mM dithiothrei-
tol. Efficiency of separation of cytosolic and mitochon-
drial fractions was confirmed by gel electrophoresis and
immunoblotting using the mitochondria specific cyto-
chrome c oxidase antibody (from Molecular Probes).BMC Complementary and Alternative Medicine 2006, 6:30 http://www.biomedcentral.com/1472-6882/6/30
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Results
Control of proliferation and cell cycle progression by I'm-
Yunity™ (PSP) in HL-60 and U-937 cells
In previous studies, we demonstrated in HL-60 cells that
aqueous extracts of I'm-Yunity™ (PSP) exerted more
potent growth inhibitory and apoptosis-inducing effects,
compared to 70% ethanolic extracts [28]. Moreover, the
reduction in proliferation was accompanied by accumula-
tion of cells in G1 simultaneous with a reduction in pro-
portion of cells in the S phase [28]. To investigate whether
the growth inhibitory effects of aqueous extracts of I'm-
Yunity™ (PSP) can be extended to other myeloid leukemia
cells, increasing concentrations of water extracts was
added to U-937 cells. A 72 h treatment resulted in signifi-
cant inhibition of cell proliferation (Figure 2A). Time
course studies showed that suppression of growth was evi-
dent as early as 24 h after treatment (data not shown). Fur-
thermore, suppression of proliferation was accompanied
by a decrease in cell viability using high but not low doses
(Figure 2B) of water extracts of I'm-Yunity™ (PSP), sug-
gesting that the polysaccharo-peptide exerts complex anti-
cellular effects in the U-937 cells. Similar to our previous
observations [28], treatment of HL-60 cells with the same
dose range of water extracts of I'm-Yunity™ (PSP) was
accompanied by a pronounced inhibition of cell growth
and viability (Figure 2C and 2D).
To explore further the manner by which extracts of I'm-
Yunity™ (PSP) affected cell growth in these two cell types,
flow cytometric analysis was performed and the results
illustrated in Figure 3A. In U-937 cells, low dose (0.1 mg/
ml) induced an accumulation of cells in the S phase, con-
comitant with a decrease in proportion of cells in the G1
phase (Figure 3A). At higher concentrations (0.5 and 1.0
mg/ml), however, a reduction in S phase, together with an
increase in G2M phases of the cell cycle was observed.
These results provide further support for the notion that a
complex mechanism underlies the interaction between
Control of cell growth and viability in U-937 and HL-60 cells by water extracts of I'm-Yunity™ (PSP) Figure 2
Control of cell growth and viability in U-937 and HL-60 cells by water extracts of I'm-Yunity™ (PSP). Both cell types were cul-
tured and treated with different dose of I'm-Yunity™ (PSP) as described in Materials and Methods. Panels A and C show sup-
pression of proliferation of U-937 (panel A) and HL-60 (panel C) cells by increasing concentrations of I'm-Yunity™ (PSP). 
Panels B and D show reduction of cell viability in U-937 (panel B) and HL-60 (panel D) by I'm-Yunity™ (PSP). Results in panels 
A-D represent average ± SD of 3–4 experiments.
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extracts of I'm-Yunity™ (PSP) and U-937 cells. In HL-60
cells, however, a dose-dependent increase in G1, accompa-
nied by a marked reduction in S phase of the cell cycle
resulted from treatment with water extracts of I'm-Yunity™
(PSP) (Figure 3A). These results raise the possibility that
water extracts of I'm-Yunity™ (PSP) target both cell cycle
checkpoints, as a likely contributing factor for its anti-pro-
liferative activities in tumor cells. To gain further insights
on how water extracts of I'm-Yunity™ (PSP) might trigger
G1/S cell cycle arrest in HL-60 cells, we determined the
expression of the retinoblastoma gene product Rb, known
to play a pivotal role in controlling the G1/S phase transi-
tion via a cyclin kinase-mediated, switch on/off mecha-
nism of the binding of transcription factor E2F [33,43,44].
Immunoblot analysis showed a dose-dependent inhibi-
tion of Rb expression in treated cells (Figure 3B). The
extent of reduction of Rb was correlated with the observed
cell cycle changes, suggesting that the attenuation of Rb
Effects of water extracts of I'm-Yunity™ (PSP) on cellular DNA content frequency histograms showing the cell cycle phase dis- tribution changes and induction of apoptosis in U-937 and HL-60 cells treated for 3 days of treatment with 0, 0.1, 0.5 and 1.0  mg/ml I'm-Yunity™ (PSP) are presented in panel A Figure 3
Effects of water extracts of I'm-Yunity™ (PSP) on cellular DNA content frequency histograms showing the cell cycle phase dis-
tribution changes and induction of apoptosis in U-937 and HL-60 cells treated for 3 days of treatment with 0, 0.1, 0.5 and 1.0 
mg/ml I'm-Yunity™ (PSP) are presented in panel A. Flow cytometric analysis was performed as described in Materials and 
Methods and results shown represent average ± SD of 2 separate experiments. Panel B. Effects of I'm-Yunity™ (PSP) on Rb 
expression in treated HL-60 cells. Relative changes in expression of Rb in control and days 1–3 treated cells were determined 
by Western blot analysis as described in Materials and Methods. The intensity of the Rb and actin immunoreactive bands was 
quantitated by densitometry and the actin-adjusted Rb expression levels are presented as fold differences, with the control 
value for each day of treatment showing as 1.
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expression likely plays a critical role in restricting cell pro-
gression from G1 to S phase, in HL-60 cells.
Induction of apoptosis in I'm-Yunity™ (PSP)-treated HL-
60 cells
Treatment with high dose (1.0 mg/ml) of water extracts of
I'm-Yunity™ (PSP) for 3 days also resulted in the induc-
tion of apoptosis in both U-937 and HL-60 cells, as evi-
dent by the appearance of cells displaying fractional DNA
contents in flow cytometric analysis (Figure 4A), and fur-
ther supported by the cleavage of DNA repair enzyme
PARP from its native 112-kDa form to an inactive 89-kDd
product (Figure 4B). Since disruption of the mitochon-
dria, accompanied by changes in the relative subcellular
distribution of apoptogenic and anti-apoptotic regulatory
proteins, has been suggested as being among the key
Changes in cell cycle phase distribution and apoptogenic/anti-apoptotic regulatory proteins in control and I'm-Yunity™ (PSP)- treated HL-60 cells Figure 4
Changes in cell cycle phase distribution and apoptogenic/anti-apoptotic regulatory proteins in control and I'm-Yunity™ (PSP)-
treated HL-60 cells. Panel A. Cellular DNA content frequency histograms showing the cell cycle phase distribution changes of 
U-937 and HL-60 cells following 3 day treatment with 1.0 mg/ml doses of I'm-Yunity™ (PSP). Flow cytometric analysis was per-
formed as described in Materials and Methods. Induction of apoptosis in treated cells is illustrated by cells showing fractional 
DNA content. Panels B-C, changes in apoptogenic/anti-apoptotic proteins in control and 3 day I'm-Yunity™ (PSP)-treated HL-
60 cells. Expression of bax, cytochrome c, bcl-2, survivin, and PARP, identified by their respective molecular weights, was 
determined by immunoblot analysis, then adjusted for protein loading using cytochrome c oxidase in panel B, or actin in panel 
C, and presented as fold differences, with the control value showing as 1. Panel D, changes in bax, bcl-2 and cytochrome c in 
the cytosolic and mitochondria fractions separated using the procedure detailed in Materials and Methods. Expression of the 
various proteins was adjusted for loading using either cytochrome c oxidase (for mitochondria fraction) or actin (for cytosolic 
fraction) and presented as fold differences, with the control value showing as 1. The adjusted bax and bcl-2 values were used to 
calculate the ratio of bax/bcl-2 expression.
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events that occur during apoptosis [37,45-50], we ana-
lyzed in detail changes in expression of apoptogenic and
anti-apoptotic proteins, notably, bax, cytochrome c, sur-
vivin, and bcl-2. Figure 4C shows composite changes in
these proteins in day 3, 0.1 and 0.5 mg/ml I'm-Yunity™
(PSP)-treated whole cell lysates. A pronounced increase in
bax and cytochrome c was clearly observed, which corre-
sponded to significant decreases in levels of bcl-2 and sur-
vivin. As additional proof of the observed protein
changes, we analyzed bax, bcl-2 and cytochrome c in the
mitochondria and cytosolic fractions. Figure 4D shows
dose-dependent increases in the expression of bax in
mitochondria and correspondingly cytochrome c in the
cytosol; purity of separation into the respective subcellu-
lar compartments was supported by the distinctive pres-
ence of cytochrome c oxidase in the mitochondria and its
absence in the cytosolic fraction. Induction of apoptosis is
further demonstrated by dose-dependent I'm-Yunity™
(PSP)-elicited increase in ratio of bax/bcl-2 (Figure 4D).
Dose-dependent increase of bax and correspondingly,
reduction in bcl-2 expression can be detected as early as
30–36 hours after treatment (data not shown).
Down-regulation of NF-κB by water extracts of I'm-
Yunity™ (PSP)
NF-κB is a transcription factor that has been implicated in
the control of cell growth [51-53]. Constitutive activation
of the NF-κB family of transcription factors in various
human tumors has been hypothesized to contribute to the
development and/or progression of malignancy by regu-
lating the expression of gene sets involved in cell growth
and proliferation, circumvention of apoptosis, and the
induction of angiogenesis and metastasis [52,53]. We
therefore measured changes in the steady state level of NF-
κB in HL-60 cells treated with water extracts of I'm-
Yunity™ (PSP). Pronounced decreases in p65 form and to
a lesser degree also p50 form of NF-κB was found in I'm-
Yunity™ (PSP)-treated HL-60 cells in day 3, varying doses
of I'm-Yunity™ (PSP)-treated cells (Figure 5A). Figure 5B
showed the quantitive determination of changes in both
p65 and p50 forms of NF-κB using a single dose of 0.5
mg/ml water extracts of I'm-Yunity™ (PSP).
NF-κB is involved in transcriptional control of cyclooxy-
genase 2 (COX2) [54-57]. Therefore, to obtain informa-
tion on functional consequences associated with the
suppression of NF-κB by I'm-Yunity™ (PSP), we deter-
mined COX2 expression using quantitative real-time and
semi-quantitative RT-PCR. Results in Figure 6 showed that
HL-60 cells treated with water extracts of I'm-Yunity™
(PSP) were accompanied by a 65–85% reduction in COX2
expression, depending on the assays used.
Modulation of extracellular signaling protein expression 
by I'm-Yunity™ (PSP)
Survival of cells in multicellular organisms is inextricably
linked to and dependent on cues from extracellular
growth factors. Availability of growth factors and signal-
ing events they elicit contribute to the homeostatic bal-
ance between cell proliferation and death. In tumor cells,
their endowment with oncogenes together with the hyper-
active status of oncogene products often result in ampli-
fied and/or persistently activated growth and survival
pathways.
Cultured tumor cells incubated with extracts of I'm-
Yunity™ (PSP) are accompanied by significant changes in
the expression of several important growth modulators
and cytokines [28]. Similarly, patients treated with I'm-
Yunity™ (PSP) showed increases in interferon-γ expres-
sion, a cytokine known to have profound immune regula-
tory properties [25]. Conceivably, interferon-γ could
contribute to the suppression of tumorigenesis indirectly,
through modulation of the immune system, as well as
directly by exerting anti-proliferative and pro-apoptotic
effects. Both mechanisms, in principle, may invoke regu-
lation of gene expression mediated through the STAT (sig-
nal transducer and activator of transcription) proteins
[58-62]. Recent studies have shown, for example, that
STAT1, as a member of the STAT protein family, plays a
vital role in the control of apoptosis; namely, lym-
phocytes from STAT1-/- mice failed to undergo apoptosis,
had reduced cytokine processing and apoptogenic pro-
teins caspase 1 and 11, and demonstrated increased pro-
liferation  in vitro, compared to cells from wild-type
animals [63].
It is therefore of interest to determine whether treatment
of HL-60 cells with water extract of I'm-Yunity™ (PSP)
may lead to changes in STAT1. Immunoblot analysis
showed a dose-dependent STAT1 increase in day 3, I'm-
Yunity™ (PSP)-treated cells (Figure 7). In contrast, analysis
of another prominent survival pathway, mediated by the
extracellular signal-regulated kinase (ERK), showed that
treatment with I'm-Yunity™ (PSP) reduced levels of acti-
vated, phosphorylated ERK, while total ERK was
unchanged, compared to control cells (Figure 7).
Discussion
A significant percentage of the estimated two million
deaths recorded in the United States each year are attrib-
utable to cancer and its ensuing complications. Cancer
presents clinically as a constellation of diseases and at all
stages – from primary prevention to treatment – can be
profoundly and significantly affected by nutrition and
diets. The existence of such a link is well supported by dec-
ades of epidemiological studies showing that the con-
sumption of plant-based diets is directly associated withBMC Complementary and Alternative Medicine 2006, 6:30 http://www.biomedcentral.com/1472-6882/6/30
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reduced risk of cancer [64-76]. The impact of nutrition
and diets in prevention of carcinogenesis is formally con-
ceptualized in chemoprevention by Sporn and others in
the 1970s, which emphasizes the use of pharmacologic or
natural agents to inhibit development or progression of
invasive cancer [67-69,71,72,74,77-79]. Research in
recent years has begun to focus on "bioactive com-
pounds" in diets with chemopreventive attributes and
delineation of their mechanism(s) [67,70,72].
Efficacy of chemopreventive agents may have multiple
mechanistic bases: reversal of abnormal differentiation,
suppression of cell replication/growth, and induction of
apoptosis. Additionally, inhibition of carcinogen activa-
tion and increase in their removal by detoxification
enzymes are also considered prudent cancer prevention
strategies [71,72,74]. Since many of the very same chem-
opreventive attributes are found in I'm-Yunity™ (PSP), we
propose that it, as an example of mushroom and mush-
room products, may be included in this category of die-
tary agents. Indeed, based results from this
communication and earlier studies, it may be suggested
that I'm-Yunity™ (PSP) is an easily compliant adjunctive
treatment particularly germane to human leukemia and
other blood-borne hematologic malignancies. Since
polysaccharide moieties predominate in I'm-Yunity™
(PSP), it is possible that less chemo- and radio-resistant
clones will result from treatment using such an agent.
The cellular changes reported in this communication as a
result of treatment with water extracts of I'm-Yunity™
(PSP) can be explained by the multiple effects it elicits,
which include suppression of the retinoblastoma tumor
suppressor protein Rb, increased release of cytochrome c
Regulation of expression of NF-κB in HL-60 cells by water extracts of I'm-Yunity™ (PSP) Figure 5
Regulation of expression of NF-κB in HL-60 cells by water extracts of I'm-Yunity™ (PSP). Control and 3 day I'm-Yunity™ 
(PSP) treated cells were harvested and total protein extracts were prepared, separated by SDS-PAGE and analyzed for expres-
sion of NF-κB p65, p50 and actin by immunoblot analysis (panel A). Time-dependent changes in actin-adjusted, NF-κB expres-
sion by water extracts of I'm-Yunity™ (PSP) are shown in panel B.
0
20
40
60
80
100
120
0
20
40
60
80
100
control
0.5
0
10
20
30
40
50
control
0.5
NF-NB( p 6 5 )
P r
o t e i n
e x p r e s s i o n
( A r b i t r a r y
u n i t )
NF-NB (p65)
NF-NB (p50)
Actin
0  0.1 0.3 0.5   0  0.1  0.3 0.5  mg/ml
P
r
o
t
e
i
n
 
e
x
p
r
e
s
s
i
o
n
 
(
%
 
o
f
 
c
o
n
t
r
o
l
)
NF-NB (p65)           NF-NB (p50)
NF-NB( p 5 0 )
1      2            3
Time (day)
P
r
o
t
e
i
n
 
e
x
p
r
e
s
s
i
o
n
(
A
r
b
i
t
r
a
r
y
 
u
n
i
t
)
1      2            3
Time (day)
mg/ml
mg/ml
A                                                      B
65-kDa
50-kDa
44-kDa
Day 3
0         0.1 0.3        0.5      mg/mlBMC Complementary and Alternative Medicine 2006, 6:30 http://www.biomedcentral.com/1472-6882/6/30
Page 10 of 15
(page number not for citation purposes)
from mitochondria to the cytosol, reduced expression of
anti-apoptotic protein bcl-2 and survivin, and simultane-
ously, increase in bax, as well as a disruption in cell sign-
aling events, as collectively depicted in the scheme in
Figure 8.
A number of new molecular targets and mechanistic
insights have surfaced from the present studies. First and
foremost is the observation that I'm-Yunity™ (PSP) down-
regulates the expression of NF-κB in HL-60 cells, thereby
identifying a new, novel molecular target of this family of
bioactive polysaccharo-peptides. It is noteworthy that the
effect of I'm-Yunity™ (PSP) on NF-κB correlated well with
the suppression of growth, suggesting a causal relation-
ship. NF-κB is a transcription factor known to be function-
ally associated with cell survival; its constitutive activation
in various human malignancies contributes to tumor
transformation, development, and progression. These
effects may relate to the ability of NF-κB to control the
transcription of genes involved in cell growth and prolif-
eration, suppression or escape of apoptosis, acquisition of
new vasculature and blood supply, and dissemination to
distant location for further growth and colony formation
[52-56]. Treatment of HL-60 cells with water extract of
I'm-Yunity™ (PSP) caused a precipitous reduction in p65
and to a lesser degree also p50 subunits of NF-κB (Figure
5). This finding is significant since it proffers the notion
that this family of polysaccharo-peptides acts in part by
forestalling a pivotal factor required for the survival and
propagation of tumor cells. The more pronounced decline
in p65 relative to p50 may relate to the fact that these two
subunits of NF-κB are known to be different gene prod-
ucts and not necessarily regulated in a coordinate fashion.
Studies have shown, for example, that p50 is proteolyti-
cally derived from a p105 precursor and hence, in princi-
ple, could be subjected to more complex mechanism of
control, compared to the p65 subunit. Taking these into
consideration, it is entirely possible that the p65 and p50
subunits are differentially regulated depending on the
dose of I'm-Yunity™ (PSP) used for treating the cells. Con-
ceivably, therefore, low rather than high doses of I'm-
Yunity™ (PSP) are effective in suppressing the expression
of the p50 subunits. In contrast, a broader dose range of
I'm-Yunity™ (PSP) affects the expression of the p65 subu-
nit. It should also be pointed out that our findings do not
necessarily contradict the role of I'm-Yunity™ (PSP) as an
immune modulator, and similarly, other data pointing to
NF-κB as a tumor suppressor rather than a promoter of
tumorigenesis [52,54]. It may well be that in normal
immune cells, I'm-Yunity™ (PSP) at an appropriate dose
range does indeed increases the expression of NF-κB and
thereby promotes the increased transcription of genes in
immune cells conducive to a heightened immune status.
The same cell type consideration may equally apply to
Relative changes in STAT1 and ERK levels in I'm-Yunity™  (PSP)-treated HL-60 cells Figure 7
Relative changes in STAT1 and ERK levels in I'm-Yunity™ 
(PSP)-treated HL-60 cells. Control and treated cells were 
harvested and total protein extracts were prepared, sepa-
rated by SDS-PAGE and analyzed for expression of STAT1 
and ERK by western blot analysis, with actin expression used 
to adjust for protein loading.
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were harvested and expression of COX2 was determined 
quantitatively by real-time PCR (panel A) and semi-quantita-
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COX2 in panel B was also adjusted using expression of 
GAPDH and presented as fold differences, with 1 represent-
ing the value in control cells.
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recent evidence showing that NF-κB can function as a
tumor suppressor by actively repressing anti-apoptotic
genes. The acquisition of a non-conventional role for NF-
κB, i.e., functioning in tumor suppression rather than pro-
motion, may also depend on stimuli impinging on cells,
and just as plausible, the co-expression of genes acting in
concert with NF-κB to facilitate transcriptional repressor
of anti-apoptotic genes. It has been demonstrated, for
example, that ARF (ADP-ribosylation factor) and p53 as
well as certain inducers of NF-κB DNA-binding activity,
such as ultraviolet light and some chemotherapeutic com-
pounds, can induce the association of NF-κB subunits
with transcriptional corepressor complexes, allowing
them to function as repressors rather than activators of
gene expression [80-82]. Whether these considerations
can apply to HL-60 cells, known to have p53-null status
but do express the ARF [83-89], in the context of cellular
effects elicited by I'm-Yunity™ (PSP) remain to be studied.
Further research will also focus on investigation of
detailed changes in steady state levels and subcellular dis-
tribution of NF-κB, using control and treated cells harbor-
ing a stably transfected dominant-negative IκB gene in
which amino acid serine at positions 32 and 34 of IκB is
mutated to amino acid alanine. These changes should
exclude its phosphorylation by IκB kinase, which is
required for the degradation of IκB, coincident with the
cytoplasm-to-nucleus translocation of NF-κB [51,90,91].
A second new finding revealed in the present studies is the
ability of I'm-Yunity™ (PSP) to down regulate COX2
expression. Persistent chronic inflammation plays an
important role in carcinogenesis [92-94]. In the early
phase of inflammation, COX2 facilitates the production
of inflammatory prostaglandins. COX2 has been shown
to be overexpressed in a variety of cancers [95-97]. Fur-
ther, there is compelling evidence from in vitro experimen-
tal studies that inhibition of COX2 decreases cellular
proliferation, increases apoptosis, and modulates genes
Proposed mechanism of action of I'm-Yunity™ (PSP) Figure 8
Proposed mechanism of action of I'm-Yunity™ (PSP). In this model, the ability of water extracts of I'm-Yunity™ (PSP) to inhibit 
cell proliferation and induce apoptosis in cancer cells is hypothesized to involve multiple effects, including 1) disruption of cell 
cycle control machinery, 2) perturbation in apoptogenic/anti-apoptotic regulatory protein expression promoting the induction 
of apoptosis, 3) alteration in mitogenic signaling pathways, 4) regulation of gene expression, exemplified by suppression of cell 
survival transcription factor NF-κB.
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involved in cell cycle regulation [93,94]. Therefore we
measured COX2 expression in control and treated cells.
Results in Figure 6 show that COX2 expression was signif-
icantly suppressed by treatment with water extracts of I'm-
Yunity™ (PSP).
A third important observation relates to the modulation
of potent signaling molecules by I'm-Yunity™ (PSP), as
exemplified by an increase the expression of STAT1 in par-
allel with the suppression of the phosphorylated form of
ERK (Figure 7). STATs and their protein partners JAKs
(Janus kinases) are evolutionarily conserved signaling and
cellular communication molecules that enable cytokines
to mount a repertoire of host defenses and immunologi-
cal responses. Similarly, ability of cells to respond to extra-
cellular challenges also depend upon signaling pathways
governed by the MAP kinase modules, with sequentially
acting protein kinases including ERK as the archetypal
form. In both examples, interaction of ligand or an exter-
nal challenge with membrane-associated receptors are
considered to be key initiation events. Because of the
importance of the STAT and ERK signaling pathways in
homeostatic control of cells, as discussed, it is of interest
and pertinent to ask how they might be affected by I'm-
Yunity™ (PSP). One possibility is that I'm-Yunity™ (PSP),
having structural similarity to proteoglycans [4], act
directly as agonists/antagonists of specific surface receptor
ligands, and in turn, augment the trigger of the JAK/STAT
signaling pathway while concurrently dampen the events
directed to the ERK signaling cascade. A second possibility
is that I'm-Yunity™ (PSP) functions as a growth factor/
cytokine decoy to sequester/trap the relevant growth fac-
tor/cytokine required for HL-60 cellular function, or bind
the pertinent receptor in ways that block further engage-
ment and interaction with their physiological, cognate lig-
ands. This possibility may be supported by structural
resemblance existing between the bioactive constituents
present in I'm-Yunity™ (PSP) with proteoglycans occur-
ring in the extracellular matrix of cancer cells [98]. As
mentioned in the Introduction, a broad spectrum of bio-
active molecules, ranging from those with defined struc-
tures and functions, e.g., proteases, nucleases, to others
with heterogeneous structures and ill-defined activities,
e.g., polysaccharo-peptides and polysaccharides, have
been identified and isolated from mushrooms
[2,4,99,100]. Finally, it is possible that I'm-Yunity™ (PSP)
exerts its effect on STAT1 and ERK by disrupting intracel-
lular signaling events, secondary to its internalization that
may involve the formation of a complex between the
polysaccharo-peptides with specific components in the
serum to facilitate its uptake into cells. This mechanism
may draw analogy from lipid-mediated delivery of highly
charged and heterogeneous plasmid DNA into cultured
mammalian cells and as vaccines [101], as well as the
intestinal absorption of oral heparin (a heterogeneous,
charged mucopolysaccharide) [102-104] or heparan sul-
fate, e.g., chondroitin sulfate [105-107]. Notably, some of
these possibilities can be tested experimentally and are
being considered for further investigation in our labora-
tory.
Conclusion
Treatment of human leukemia cells by water extracts of
I'm-Yunity™ (PSP) causes cell cycle arrest and alterations
in the expression of apoptogenic/anti-apoptotic and
extracellular signaling regulatory proteins, the net result
being a reduction in proliferation and an increase in
apoptosis. These findings may be part of the mechanisms
that underlie or contribute to its reported clinical
attributes and overall health benefits.
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